Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation
Pathogens · 2024-05-30 · 13 (6) · 461
DOI: 10.3390/pathogens13060461 ↗At a glance
Übersichtsarbeit in Pathogens, published online on 2024-05-30. Written by Mary Garvey. Institution: Department of Life Science, Atlantic Technological University, F91 YW50 Sligo, Ireland. Major MEDLINE topics: Sepsis, Cross Infection. Cited 24 times so far (Crossref); 138 references. The full text is freely available (open access, CC BY 4.0).
Topics: Sepsis
Abstract (original language)
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, commonly associated with nosocomial transmission. Gram-negative bacterial species are particularly problematic due to the release of the lipopolysaccharide toxins upon cell death. The lipopolysaccharide toxin of E. coli has a greater immunogenic potential than that of other Gram-negative bacteria. The resultant dysregulation of the immune system is associated with organ failure and mortality, with pregnant women, ICU patients, and neonates being particularly vulnerable. Additionally, sepsis recovery patients have an increased risk of re-hospitalisation, chronic illness, co-morbidities, organ damage/failure, and a reduced life expectancy. The emergence and increasing prevalence of antimicrobial resistance in bacterial and fungal species has impacted the treatment of sepsis patients, leading to increasing mortality rates. Multidrug resistant pathogens including vancomycin-resistant Enterococcus, beta lactam-resistant Klebsiella, and carbapenem-resistant Acinetobacter species are associated with an increased risk of mortality. To improve the prognosis of sepsis patients, predominantly high-risk neonates, advances must be made in the early diagnosis, triage, and control of sepsis. The identification of suitable biomarkers and biomarker combinations, coupled with machine learning and artificial intelligence, show promise in early detection protocols. Rapid diagnosis of sepsis in patients is essential to inform on clinical treatment, especially with resistant infectious agents. This timely review aims to discuss sepsis prevalence, aetiology, and recent advances towards disease mitigation and control.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Life Science, Atlantic Technological University, F91 YW50 Sligo, Ireland.
- Centre for Precision Engineering, Materials and Manufacturing Research (PEM), Atlantic Technological University, F91 YW50 Sligo, Ireland.
ORCID profiles: Mary Garvey
Cite
APA
Garvey, M. (2024). Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation. Pathogens, 13(6), 461. https://doi.org/10.3390/pathogens13060461
Vancouver
Garvey M. Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation. Pathogens. 2024;13(6):461. doi:10.3390/pathogens13060461
BibTeX
@article{Garvey2024,
author = {Garvey, Mary},
title = {Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation},
journal = {Pathogens},
year = {2024},
volume = {13},
number = {6},
pages = {461},
doi = {10.3390/pathogens13060461}
}
EUVIMED